mannkind

MannKind to Present at Upcoming Conferences

April 27, 2010 4:00 AM EDT MannKind to Present at Upcoming Conferences

VALENCIA, Calif., Apr 27, 2010 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.

- Deutsche Bank 35th Annual Health Care Conferenceon Tuesday, May 4, 2010 at 4:50 PM (EDT) at the InterContinental in Boston, MA
- Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 12, 2010 at 3:00 PM (EDT) at the Grand Hyatt in New York, NY
- Rodman & Renshaw 6th Annual Global Healthcare Conference on Monday, May 17, 2010 at 10:40 AM (London Time) at the Grosvenor House Hotel in London, UK

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with

diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted an NDA to the FDA requesting approval of AFREZZA for the treatment of adults with Type 1 or Type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response from the FDA regarding this NDA seeking additional information about AFREZZA. Currently, AFREZZA remains under regulatory review. Other products in its pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at http://www.mannkind.corp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation Matthew J. Pfeffer Corporate Vice President and Chief Financial Officer 661-775-5300 mpfeffer@mannkindcorp.com